Vericel CORP Form 4 insider transactions

Sean C. Flynn, Chief Legal Officer of Vericel Corp, reports the sale of 3,835 shares of common stock at $57.32 per share and the acquisition of 35,000 stock options and 14,000 restricted stock units.

Michael Halpin, Chief Operating Officer of Vericel Corp, reports the acquisition of stock options and restricted stock units.

Chief Financial Officer Joseph Mara acquired stock options and restricted stock units in Vericel Corp on February 20, 2025.

Jonathan Mark Hopper, Chief Medical Officer of Vericel Corp, reports the acquisition of stock options and restricted stock units on February 20, 2025.

Dominick Colangelo, President and CEO of Vericel Corp, reports acquisition of stock options and restricted stock units.

Chief Medical Officer Jonathan Hopper reports transactions involving Vericel Corp stock, including the vesting of Restricted Stock Units (RSUs) and subsequent acquisition and disposal of shares to cover tax obligations.

Dominick Colangelo, President and CEO of Vericel Corp, reports the acquisition and disposal of common stock and restricted stock units (RSUs) following recent vesting events.

Chief Legal Officer Sean C. Flynn reports acquisition and disposal of Vericel Corp stock and restricted stock units due to vesting and tax withholding.

Chief Financial Officer Joseph Mara of Vericel Corp reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Operating Officer Michael Halpin reports acquisition and disposal of Vericel Corp stock related to vesting of Restricted Stock Units (RSUs) and tax withholding.

Principal Accounting Officer Jonathan Siegal of Vericel Corp reports acquisition and disposal of common stock and restricted stock units.

Director Kevin McLaughlin exercised stock options and sold shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.

Director Alan Rubino exercised stock options to acquire 19,000 shares of Vericel Corp common stock on February 7, 2025.

Director Robert Zerbe exercised stock options and sold shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.

Principal Accounting Officer Jonathan Siegal of Vericel Corp reports exercising stock options and selling shares under a pre-arranged trading plan.

Vericel Corp's Principal Accounting Officer, Jonathan Siegal, exercised stock options and sold shares under a pre-arranged trading plan.

Vericel Corporation director Paul Wotton sold 2,600 shares of common stock at a price of $58.72 per share on December 4, 2024.

Vericel Corp's Chief Medical Officer, Jonathan Hopper, exercised stock options and sold 10,000 shares of common stock on December 2, 2024, according to a recent SEC filing.

Robert Zerbe, a director at Vericel Corp, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

A Vericel Corp director, Kevin McLaughlin, exercised stock options and sold shares on November 13, 2024, under a pre-arranged 10b5-1 trading plan.

Vericel Corp's CEO, Dominick Colangelo, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Robert Zerbe, a director at Vericel Corp, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Heidi Hagen exercised stock options to acquire 10,000 shares of Vericel Corp common stock at a price of $3.74 per share on October 17, 2024.

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Steven Gilman reports exercising stock options and selling shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.

Director Steven Gilman exercised stock options and sold shares of Vericel Corp common stock on October 2, 2024, according to a Form 4 filing with the SEC.

Principal Accounting Officer Jonathan Siegal of Vericel Corp reports acquisition and disposal of common stock and vesting of Restricted Stock Units (RSUs).

Director Steven Gilman exercised stock options and sold shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.

Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Steven Gilman reports exercising stock options and selling shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.